Cargando…

Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy

Background: Cholestasis is a common pathological process in a variety of liver diseases that may lead to liver fibrosis, cirrhosis, and even liver failure. Cholestasis relief has been regarded as a principal target in the management of multiple chronic cholestasis liver diseases like primary scleros...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Shuailing, Li, Xiao, Geng, Chong, Guo, Yaoyu, Yang, Yi, Wang, Chunhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203247/
https://www.ncbi.nlm.nih.gov/pubmed/37229242
http://dx.doi.org/10.3389/fphar.2023.1171512
_version_ 1785045590705438720
author Song, Shuailing
Li, Xiao
Geng, Chong
Guo, Yaoyu
Yang, Yi
Wang, Chunhui
author_facet Song, Shuailing
Li, Xiao
Geng, Chong
Guo, Yaoyu
Yang, Yi
Wang, Chunhui
author_sort Song, Shuailing
collection PubMed
description Background: Cholestasis is a common pathological process in a variety of liver diseases that may lead to liver fibrosis, cirrhosis, and even liver failure. Cholestasis relief has been regarded as a principal target in the management of multiple chronic cholestasis liver diseases like primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) at present. However, complicated pathogenesis and limited acknowledgments fettered therapeutic development. Therefore, this study aimed to systematically analyze miRNA-mRNA regulatory networks in cholestatic liver injury in order to provide new treatment strategies. Methods: Gene Expression Omnibus (GEO) database (GSE159676) was used to screen differentially expressed hepatic miRNAs and mRNAs in the PSC vs. control comparison and the PBC vs. control comparison, respectively. MiRWalk 2.0 tool was used to predict miRNA-mRNA pairs. Subsequently, functional analysis and immune cell infiltration analysis were performed to explore the pivotal functions of the target genes. RT-PCR was used to verify the result. Results: In total, a miRNA-mRNA network including 6 miRNAs (miR-122, miR-30e, let-7c, miR-107, miR-503, and miR-192) and 8 hub genes (PTPRC, TYROBP, LCP2, RAC2, SYK, TLR2, CD53, and LAPTM5) was constructed in cholestasis. Functional analysis revealed that these genes were mainly involved in the regulation of the immune system. Further analysis revealed that resting memory CD4 T cells and monocytes could potentially participate in cholestatic liver injury. The expressions of DEMis and eight hub genes were verified in ANIT-induced and BDL-induced cholestatic mouse models. Furthermore, SYK was found to have an impact on the response to UDCA, and its mechanism was possibly associated with complement activation and monocyte reduction. Conclusion: In the present study, a miRNA-mRNA regulatory network was constructed in cholestatic liver injury, which mostly mediated immune-related pathways. Moreover, the targeted gene SYK and monocytes were found to be related to UDCA response in PBC.
format Online
Article
Text
id pubmed-10203247
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102032472023-05-24 Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy Song, Shuailing Li, Xiao Geng, Chong Guo, Yaoyu Yang, Yi Wang, Chunhui Front Pharmacol Pharmacology Background: Cholestasis is a common pathological process in a variety of liver diseases that may lead to liver fibrosis, cirrhosis, and even liver failure. Cholestasis relief has been regarded as a principal target in the management of multiple chronic cholestasis liver diseases like primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) at present. However, complicated pathogenesis and limited acknowledgments fettered therapeutic development. Therefore, this study aimed to systematically analyze miRNA-mRNA regulatory networks in cholestatic liver injury in order to provide new treatment strategies. Methods: Gene Expression Omnibus (GEO) database (GSE159676) was used to screen differentially expressed hepatic miRNAs and mRNAs in the PSC vs. control comparison and the PBC vs. control comparison, respectively. MiRWalk 2.0 tool was used to predict miRNA-mRNA pairs. Subsequently, functional analysis and immune cell infiltration analysis were performed to explore the pivotal functions of the target genes. RT-PCR was used to verify the result. Results: In total, a miRNA-mRNA network including 6 miRNAs (miR-122, miR-30e, let-7c, miR-107, miR-503, and miR-192) and 8 hub genes (PTPRC, TYROBP, LCP2, RAC2, SYK, TLR2, CD53, and LAPTM5) was constructed in cholestasis. Functional analysis revealed that these genes were mainly involved in the regulation of the immune system. Further analysis revealed that resting memory CD4 T cells and monocytes could potentially participate in cholestatic liver injury. The expressions of DEMis and eight hub genes were verified in ANIT-induced and BDL-induced cholestatic mouse models. Furthermore, SYK was found to have an impact on the response to UDCA, and its mechanism was possibly associated with complement activation and monocyte reduction. Conclusion: In the present study, a miRNA-mRNA regulatory network was constructed in cholestatic liver injury, which mostly mediated immune-related pathways. Moreover, the targeted gene SYK and monocytes were found to be related to UDCA response in PBC. Frontiers Media S.A. 2023-05-09 /pmc/articles/PMC10203247/ /pubmed/37229242 http://dx.doi.org/10.3389/fphar.2023.1171512 Text en Copyright © 2023 Song, Li, Geng, Guo, Yang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Song, Shuailing
Li, Xiao
Geng, Chong
Guo, Yaoyu
Yang, Yi
Wang, Chunhui
Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy
title Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy
title_full Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy
title_fullStr Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy
title_full_unstemmed Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy
title_short Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy
title_sort uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203247/
https://www.ncbi.nlm.nih.gov/pubmed/37229242
http://dx.doi.org/10.3389/fphar.2023.1171512
work_keys_str_mv AT songshuailing uncoveringkeymoleculesandimmunelandscapeincholestaticliverinjuryimplicationsforpathogenesisanddrugtherapy
AT lixiao uncoveringkeymoleculesandimmunelandscapeincholestaticliverinjuryimplicationsforpathogenesisanddrugtherapy
AT gengchong uncoveringkeymoleculesandimmunelandscapeincholestaticliverinjuryimplicationsforpathogenesisanddrugtherapy
AT guoyaoyu uncoveringkeymoleculesandimmunelandscapeincholestaticliverinjuryimplicationsforpathogenesisanddrugtherapy
AT yangyi uncoveringkeymoleculesandimmunelandscapeincholestaticliverinjuryimplicationsforpathogenesisanddrugtherapy
AT wangchunhui uncoveringkeymoleculesandimmunelandscapeincholestaticliverinjuryimplicationsforpathogenesisanddrugtherapy